Barinthus Biotherapeutics plc has announced its strategic transformation focusing on immunology and inflammatory diseases, highlighting its promising immunotherapy VTP-1000 for celiac disease ...

Reports FY24 revenue $15M, consensus $10M. “We’ve entered 2025 with a refreshed strategic focus on immunological and inflammatory diseases.

Strategic transformation ongoing, positioning the Company as a focused leader in immunology and inflammatory diseasesHighly differentiated, ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...